



Specimen Details

Date collected: 03/22/2019 0842 Local
Date received: 03/22/2019
Date entered: 03/22/2019
Date reported: 03/25/2019 0405 ET

General Comments & Additional Information

Total Volume: Not Provided

Fasting: Yes

Ordered Items

NMR LipoProfile; CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel; Hemoglobin A1c; Cortisol; C-Reactive Protein, Cardiac; Insulin; Venipuncture

| TESTS | RESULT | FLAG | UNITS | REFERENCE INTERVAL | LAB |
|--|-------------|------------------------|--------|--------------------|-----|
| NMR LipoProfile | | | | | |
| LDL Particle Number | | | | | 01 |
| LDL-P | 1017 | High | nmol/L | <1000 | 01 |
| | | Low | | < 1000 | |
| | | Moderate | | 1000 - 1299 | |
| | | Borderline-High | | 1300 - 1599 | |
| | | High | | 1600 - 2000 | |
| | | Very High | | > 2000 | |
| Lipids | | | | | 01 |
| LDL-C | 70 | | mg/dL | 0 - 99 | 01 |
| | | Optimal | | < 100 | |
| | | Above optimal | | 100 - 129 | |
| | | Borderline | | 130 - 159 | |
| | | High | | 160 - 189 | |
| | | Very high | | > 189 | |
| Comment: | | | | | 01 |
| LDL-C is inaccurate if patient is non-fasting. | | | | | |
| HDL-C | 26 | Low | mg/dL | >39 | 01 |
| Triglycerides | 207 | High | mg/dL | 0 - 149 | 01 |
| Cholesterol, Total | 137 | | mg/dL | 100 - 199 | 01 |
| LDL and HDL Particles | | | | | 01 |
| HDL-P (Total) | 20.5 | Low | umol/L | >=30.5 | 01 |
| Small LDL-P | 826 | High | nmol/L | <=527 | 01 |
| LDL Size | 19.8 | Low | nm | >20.5 | 01 |

**** INTERPRETATIVE INFORMATION****

PARTICLE CONCENTRATION AND SIZE

<--Lower CVD Risk Higher CVD Risk-->

| LDL AND HDL PARTICLES | Percentile | in Reference Population |
|-----------------------|------------------------------------|------------------------------------|
| HDL-P (total) | High | 75th 50th 25th Low |
| | >34.9 | 34.9 30.5 26.7 <26.7 |
| Small LDL-P | Low | 25th 50th 75th High |
| | <117 | 117 527 839 >839 |
| LDL Size | <-Large (Pattern A)-> | <-Small (Pattern B)-> |

Patient ID:

| TESTS | RESULT | FLAG | UNITS | REFERENCE INTERVAL | LAB |
|-------|--------|------|-------|--------------------|-----|
| | 23.0 | 20.6 | 20.5 | 19.0 | |

Comment: 01

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

These assays were developed and their performance characteristics determined by LipoScience. These assays have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values have not been fully established.

Insulin Resistance Score 01

LP-IR Score 93 High <=45 01

INSULIN RESISTANCE MARKER

<--Insulin Sensitive Insulin Resistant-->

Percentile in Reference Population

Insulin Resistance Score

| LP-IR Score | Low | 25th | 50th | 75th | High |
|-------------|-----|------|------|------|------|
| | <27 | 27 | 45 | 63 | >63 |

Comment: 01

LP-IR Score is inaccurate if patient is non-fasting.

The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. The LP-IR score listed above has not been cleared by the US Food and Drug Administration.

CBC With Differential/Platelet

| | | | | |
|------------------------|------|------|-------------|----|
| WBC | 3.9 | K/uL | 3.2 - 10.6 | 02 |
| RBC | 5.63 | M/uL | 3.98 - 5.98 | 02 |
| Hemoglobin | 16.6 | g/dL | 12.5 - 18.0 | 02 |
| Hematocrit | 49.5 | % | 36.9 - 52.1 | 02 |
| MCV | 87.9 | fL | 80.6 - 97.6 | 02 |
| MCH | 29.5 | pg | 27.3 - 33.7 | 02 |
| MCHC | 33.5 | g/dL | 33.4 - 35.3 | 02 |
| RDW | 13.9 | % | 12.5 - 15.3 | 02 |
| Platelets | 266 | K/uL | 140 - 440 | 02 |
| Neutrophils | 50.0 | % | 41.0 - 81.0 | 02 |
| Lymphs | 39.2 | % | 11.0 - 44.0 | 02 |
| Monocytes | 8.2 | % | 4.0 - 11.0 | 02 |
| Eos | 1.5 | % | 0.0 - 6.0 | 02 |
| Basos | 0.8 | % | 0.0 - 1.0 | 02 |
| Neutrophils (Absolute) | 2.0 | K/uL | 1.8 - 6.8 | 02 |
| Lymphs (Absolute) | 1.5 | K/uL | 1.0 - 3.0 | 02 |
| Monocytes (Absolute) | 0.3 | K/uL | 0.2 - 1.0 | 02 |
| Eos (Absolute) | 0.1 | K/uL | 0.0 - 0.4 | 02 |
| Baso (Absolute) | 0.0 | K/uL | 0.0 - 0.1 | 02 |
| Immature Granulocytes | 0.3 | % | 0.0 - 8.0 | 02 |

Patient ID:

| TESTS | RESULT | FLAG | UNITS | REFERENCE INTERVAL | LAB |
|---|--------|------|---------|--------------------|-----|
| Immature Grans (Abs) | 0.0 | | K/uL | 0.0 - 1.9 | 02 |
| NRBC | 0 | | /100WBC | | 02 |
| Hematology Comments: | | | | | 02 |
| RDW SD | 44.9 | | fL | N | |
| MEAN PLATELET VOLUME | 10.6 | | fL | 6.2-9.8 H | |
| Comp. Metabolic Panel (14) | | | | | |
| Glucose | 79 | | mg/dL | 70 - 110 | 02 |
| BUN | 13 | | mg/dL | 7 - 18 | 02 |
| Creatinine | 0.86 | | mg/dL | 0.60 - 1.30 | 02 |
| eGFR If NonAfricn Am | 98.00 | | mL/min | | 02 |
| GFR calculation is only for patients with chronic renal insufficiency. Units of measure are ml/min/1.73 m2. | | | | | |
| Average GFR for healthy adults is >60 ml/min/1.73 m2 | | | | | |
| Chronic kidney disease if GFR is 15-60 ml/min/1.73 m2 | | | | | |
| Kidney failure if GFR is <15 ml/min/1.73 m2 | | | | | |
| MDRD calculation used. Refer to http://www.nkdep.nih.gov/healthprofessionals/index.htm | | | | | |
| eGFR If Africn Am | 126.04 | | mL/min | | 02 |
| GFR calculation is only for patients with chronic renal insufficiency. Units of measure are ml/min/1.73 m2. | | | | | |
| Average GFR for healthy adults is >60 ml/min/1.73 m2 | | | | | |
| Chronic kidney disease if GFR is 15-60 ml/min/1.73 m2 | | | | | |
| Kidney failure if GFR is <15 ml/min/1.73 m2 | | | | | |
| MDRD calculation used. Refer to http://www.nkdep.nih.gov/healthprofessionals/index.htm | | | | | |
| BUN/Creatinine Ratio | 15.1 | | Ratio | 7.0 - 24.0 | 02 |
| Sodium | 141 | | mmol/L | 136 - 145 | 02 |
| Potassium | 4.7 | | mmol/L | 3.5 - 5.1 | 02 |
| Chloride | 101 | | mmol/L | 98 - 107 | 02 |
| Carbon Dioxide, Total | 31 | | mmol/L | 23 - 32 | 02 |
| Calcium | 9.1 | | mg/dL | 8.5 - 10.1 | 02 |
| Protein, Total | 6.9 | | g/dL | 6.4 - 8.2 | 02 |
| Albumin | 4.1 | | g/dL | 3.4 - 5.0 | 02 |
| Globulin, Total | 2.8 | | g/dL | 1.8 - 3.5 | 02 |
| A/G Ratio | 1.5 | | | | 02 |
| Bilirubin, Total | 0.7 | | mg/dL | 0.1 - 1.2 | 02 |
| Alkaline Phosphatase | 58 | | U/L | 50 - 136 | 02 |
| AST (SGOT) | 23 | | U/L | 5 - 41 | 02 |
| ALT (SGPT) | 18 | | U/L | 10 - 56 | 02 |
| Lipid Panel | | | | | |
| Cholesterol, Total | 132 | | mg/dL | 0 - 200 | 02 |

Patient ID:

| TESTS | RESULT | FLAG | UNITS | REFERENCE INTERVAL | LAB |
|-----------------|--------|------|-------|--------------------|-----|
| Triglycerides | 191 | High | mg/dL | 0 - 150 | 02 |
| HDL Cholesterol | 31 | Low | mg/dL | 40 - 60 | 02 |

Male patients:

No risk >55 mg/dL
 Moderate risk = 40-55 mg/dL
 High risk <40 mg/dL

Female patients:

No risk >65 mg/dL
 Moderate risk = 45-65 mg/dL
 High risk <45 mg/dL

National Cholesterol Education Program (NCEP Guidelines:

<40mg/dL = low HDL cholesterol (major risk of CHD)
 >60 mg/dL = high HDL cholesterol (negative risk factor for CHD)

| | | | | | |
|----------------------|------|------|-------|---------|----|
| VLDL Cholesterol Cal | 38.2 | High | mg/dL | 2 - 30 | 02 |
| LDL Cholesterol Calc | 63 | | mg/dL | 0 - 130 | 02 |

Adults:

Desirable LDL <130 mg/dl
 Borderline LDL = 130-160 mg/dl
 High Risk LDL >160 mg/dl

Children <19 Years of Age:

Desirable LDL <110 mg/dl
 Borderline LDL = 110-130 mg/dl
 High Risk LDL >130 mg/dl

| | | | | | |
|-----------------------|-----|--|---|-----------|----|
| Hemoglobin A1c | 4.6 | | % | 4.2 - 6.3 | 02 |
|-----------------------|-----|--|---|-----------|----|

For management of known diabetes, Hgb A1c level goals must be individualized for each patient. Age, type of diabetes, presence of comorbid diseases, and brittleness of the disease must be considered. In general, a level of 7% is a reasonable goal.

Performance characteristics for this method have not been established or approved by the FDA for the diagnosis of diabetes.

| | | | | | |
|-----------------|------|--|-------------|------------|----|
| Cortisol | 10.0 | | ug/dL | | 03 |
| | | | Cortisol AM | 6.2 - 19.4 | |
| | | | Cortisol PM | 2.3 - 11.9 | |

| | | | | | |
|------------------------------------|--|------|------|-------------|----|
| C-Reactive Protein, Cardiac | 3.88 | High | mg/L | 0.00 - 3.00 | 03 |
| | Relative Risk for Future Cardiovascular Event | | | | |
| | | Low | | <1.00 | |

Patient ID:

| TESTS | RESULT | FLAG | UNITS | REFERENCE | INTERVAL | LAB |
|----------------|--------|------|----------------|-----------|----------|-----|
| | | | Average | 1.00 | - 3.00 | |
| | | | High | | >3.00 | |
| Insulin | 5.8 | | uIU/mL | 2.6 | - 24.9 | 03 |

| | | | |
|----|-------|--|--------------------------|
| 01 | BN | LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361 | Dir: Sanjai Nagendra, MD |
| 02 | DRAUT | Lone Peak Hospital 11925 S State Street, Draper, UT 84020-7735 | Dir: Nathan Eliason, MD |
| 03 | PDLCA | LabCorp Phoenix 5005 S 40th Street Ste 1200, Phoenix, AZ 85040-2969 | Dir: Earle Collum, MD |

For inquiries, the physician may contact **Branch: 888-522-2677 Lab: 800-762-4344**